Thromb Haemost 2008; 100(05): 727-728
DOI: 10.1160/TH-08-09-0576
Editorial Focus
Schattauer GmbH

Thyroid disease and haemostasis – a relationship with clinical implications?

Alessandro Squizzato
1   Department of Clinical Medicine, University of Insubria, Varese, Italy
2   Department of Vascular Medicine, Academic Medical Center
,
Victor E. A. Gerdes
2   Department of Vascular Medicine, Academic Medical Center
3   Department of Internal Medicine, Slotervaartziekenhuis, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 04 September 2008

Accepted 04 September 2008

Publication Date:
22 November 2017 (online)

 

 
  • References

  • 1 Squizzato A, Romualdi E, Buller HR. et al. Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
  • 2 Manfredi E, van Zaane B, Gerdes VEA. et al. Hypothyroidism and acquired von Willebrand’s syndrome: a systematic review. Haemophilia 2008; 14: 423-433.
  • 3 Kurnik D, Loebstein R, Farfel Z. et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83: 107-113.
  • 4 Van Oosterom AT, Mattie H, Hermens WT. et al. The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the rat. Thromb Haemost 1976; 35: 607-619.
  • 5 Bucerius J, Naubereit A, Joe AY. et al. Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy. Thromb Haemost 2008; 100: 803-809.
  • 6 Azar AJ, Dekkers JW, Rosendaal FR. et al. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infaction patients. Thromb Haemost 1994; 72: 347-351.